Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Orthopedics Attends 2018 Qinling Joint Surgery Master Forum

[2018-05-17] 

Xi'an, China - Shanghai MicroPort Orthopedics Co., Ltd. (“MicroPort® Orthopedics”) attended 2018 Qinling Joint Surgery Master Forum to display its hip and knee products through product samples, animation, surgical videos, and instrument demonstration. The forum gathered more than 1,000 domestic and overseas orthopedic experts to exchange ideas on the treatment and surgical technique of joint diseases as well as hot issues related with complex replacement surgeries.
 
During the meeting, MicroPort® Orthopedics hosted a satellite meeting in which Professor Jia Zheng of Henan Province People Hospital was invited to introduce SuperPath® surgical technique to the attendees based on the study of knee biomechanics and its clinical experience. In a natural knee, the medial compartment is much more stable than the lateral compartment during the normal knee flexion. The main factor for knee stability is the high geometrical conformity of the tibiofemoral joint. The lateral compartment provides "rollback" during the movement because of high compliance. Medial pivot knee is designed based on such theories. Professor Zheng pointed out, the distal portion of femur of Asian people is narrower than that of Western people due to the difference of skeletal structure. The medial pivot Stature® Femur is designed to fit in the anatomical features of Asian people. He said, the medial pivot knee can help resume the biomechanics of a natural knee to ensure the femur rotation during the flexion, which results in improved patient satisfaction after surgery.
 
MicroPort® Orthopedics Medial Pivot knee was launched in the US in 1998 with around 20 years' clinical history. Up to date, nearly 550,000 Medial Pivot knees have been implanted globally. Several long-term studies have proved the advantages of medial pivot knee in total knee arthroplasty ("TKA"). The Knee has published a study evaluating long-term clinical and radiographic outcomes of the Medial-Pivot Knee System. The results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities. The Journal of Arthroplasty has published a retrospective, comparative study that evaluated patient satisfaction after TKA using the MicroPort® Orthopedics' Evolution® Medial-Pivot Knee System and a posterior-stabilized ("PS") knee system. The study showed that patients who underwent the MP-TKA scored significantly better on the Forgotten Joint Score ("FJS") than those who underwent the PS-TKA, particularly with regard to deep knee flexion and stability of the prosthesis. With the aims to increase patient satisfaction, the medial pivot knee will serve more domestic and overseas patients. MicroPort® Orthopedics will continue to work with surgeons to provide better orthopedic solutions to patients, in accordance with our branding ideology "The Patient Always Comes First."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953
Email: ir@microport.com

 

[Prev]:MicroPort® Orthopedics Holds China-Australia Medial Pivot Knee Seminar
[Next]:Foreign Experts Visit MicroPort® During CIT 2018